Found: 84
Select item for more details and to access through your institution.
Reliability of histologic assessment in patients with eosinophilic oesophagitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 7, p. 940, doi. 10.1111/apt.14559
- By:
- Publication type:
- Article
Physicians’ perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 6, p. 773, doi. 10.1111/apt.14514
- By:
- Publication type:
- Article
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 2, p. 219, doi. 10.1111/apt.14420
- By:
- Publication type:
- Article
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 2, p. 229, doi. 10.1111/apt.14421
- By:
- Publication type:
- Article
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 2, p. 162, doi. 10.1111/apt.14422
- By:
- Publication type:
- Article
The development of a magnetic resonance imaging index for fistulising Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 5, p. 516, doi. 10.1111/apt.14190
- By:
- Publication type:
- Article
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 46, n. 3, p. 292, doi. 10.1111/apt.14164
- By:
- Publication type:
- Article
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 8, p. 1058, doi. 10.1111/apt.13995
- By:
- Publication type:
- Article
Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 5, p. 617, doi. 10.1111/apt.13913
- By:
- Publication type:
- Article
Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 3, p. 381, doi. 10.1111/apt.13886
- By:
- Publication type:
- Article
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 1, p. 50, doi. 10.1111/apt.13838
- By:
- Publication type:
- Article
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2016, v. 44, n. 2, p. 157, doi. 10.1111/apt.13653
- By:
- Publication type:
- Article
Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2016, v. 43, n. 1, p. 61, doi. 10.1111/apt.13453
- By:
- Publication type:
- Article
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 10, p. 1170, doi. 10.1111/apt.13398
- By:
- Publication type:
- Article
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 10, p. 1200, doi. 10.1111/apt.13408
- By:
- Publication type:
- Article
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 9, p. 1082, doi. 10.1111/apt.13387
- By:
- Publication type:
- Article
Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 7, p. 783, doi. 10.1111/apt.13356
- By:
- Publication type:
- Article
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 5, p. 504, doi. 10.1111/apt.13291
- By:
- Publication type:
- Article
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 3, p. 330, doi. 10.1111/apt.13251
- By:
- Publication type:
- Article
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 42, n. 2, p. 188, doi. 10.1111/apt.13243
- By:
- Publication type:
- Article
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 41, n. 8, p. 734, doi. 10.1111/apt.13139
- By:
- Publication type:
- Article
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 41, n. 5, p. 409, doi. 10.1111/apt.13076
- By:
- Publication type:
- Article
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2015, v. 41, n. 1, p. 77, doi. 10.1111/apt.13001
- By:
- Publication type:
- Article
Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECi SE 3 study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 8, p. 903, doi. 10.1111/apt.12930
- By:
- Publication type:
- Article
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 5, p. 486, doi. 10.1111/apt.12863
- By:
- Publication type:
- Article
Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2014, v. 40, n. 5, p. 477, doi. 10.1111/apt.12862
- By:
- Publication type:
- Article
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2014, v. 39, n. 10, p. 1126, doi. 10.1111/apt.12733
- By:
- Publication type:
- Article
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 10, p. 1236, doi. 10.1111/apt.12499
- By:
- Publication type:
- Article
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 5, p. 447, doi. 10.1111/apt.12407
- By:
- Publication type:
- Article
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 3, p. 255, doi. 10.1111/apt.12366
- By:
- Publication type:
- Article
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 37, n. 5, p. 546, doi. 10.1111/apt.12218
- By:
- Publication type:
- Article
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 37, n. 2, p. 204, doi. 10.1111/apt.12145
- By:
- Publication type:
- Article
Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2012, v. 36, n. 6, p. 569, doi. 10.1111/j.1365-2036.2012.05217.x
- By:
- Publication type:
- Article
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - additional results from two controlled studies.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2011, v. 34, n. 7, p. 747, doi. 10.1111/j.1365-2036.2011.04800.x
- By:
- Publication type:
- Article
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2011, v. 34, n. 3, p. 306, doi. 10.1111/j.1365-2036.2011.04717.x
- By:
- Publication type:
- Article
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 5, p. 541, doi. 10.1111/j.1365-2036.2010.04568.x
- By:
- Publication type:
- Article
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 2, p. 185, doi. 10.1111/j.1365-2036.2010.04509.x
- By:
- Publication type:
- Article
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2011, v. 33, n. 2, p. 194, doi. 10.1111/j.1365-2036.2010.04515.x
- By:
- Publication type:
- Article
The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2010, v. 32, n. 3, p. 384, doi. 10.1111/j.1365-2036.2010.04360.x
- By:
- Publication type:
- Article
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2010, v. 31, n. 12, p. 1296, doi. 10.1111/j.1365-2036.2010.04304.x
- By:
- Publication type:
- Article
Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2009, v. 30, n. 9, p. 930, doi. 10.1111/j.1365-2036.2009.04118.x
- By:
- Publication type:
- Article
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2009, v. 30, n. 3, p. 210, doi. 10.1111/j.1365-2036.2009.04027.x
- By:
- Publication type:
- Article
Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2008, v. 28, n. 6, p. 674, doi. 10.1111/j.1365-2036.2008.03753.x
- By:
- Publication type:
- Article
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2008, v. 27, n. 11, p. 1094, doi. 10.1111/j.1365-2036.2008.03688.x
- By:
- Publication type:
- Article
Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 26, n. 7, p. 987, doi. 10.1111/j.1365-2036.2007.03455.x
- By:
- Publication type:
- Article
MMX Multi Matrix System<sup>®</sup> mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 26, n. 2, p. 205, doi. 10.1111/j.1365-2036.2007.03361.x
- By:
- Publication type:
- Article
Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 25, n. 12, p. 1435, doi. 10.1111/j.1365-2036.2007.03341.x
- By:
- Publication type:
- Article
Review article: biological activity markers in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2007, v. 25, n. 3, p. 247, doi. 10.1111/j.1365-2036.2006.03184.x
- By:
- Publication type:
- Article
Systematic review: the management of pouchitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2006, v. 23, n. 8, p. 1087, doi. 10.1111/j.1365-2036.2006.02884.x
- By:
- Publication type:
- Article